Working… Menu

Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01898377
Recruitment Status : Terminated (New treatment option introduced for patients with the study indication)
First Posted : July 12, 2013
Last Update Posted : October 23, 2020
Information provided by (Responsible Party):
Seoul National University Hospital

Brief Summary:
In this study we will combine mycophenolate mofetil and imatinib mesylate to treat steroid-refractory sclerotic/fibrotic type chronic graft-versus-host disease (GVHD) to see the response rate and to find the safety of combination.

Condition or disease Intervention/treatment Phase
Chronic Graft-versus-host Disease Drug: Imatinib mesylate, Mycophenolate mofetil Phase 2

Detailed Description:

Sclerotic/fibrotic type chronic GVHD is one of the most severe forms of the disease and is frequently refractory to standard treatment approaches. Imatinib mesylate, a tyrosine kinase inhibitor, has been shown to be effective in patients with sclerotic/fibrotic type chronic GVHD by strongly inhibiting both PDGF (Platelet-derived growth factor) and TGF-β (transforming growth factor-β) intracellular signaling, which is responsible for the expression of extracellular matrix genes.

Mycophenolate mofetil (MMF) is one of effective agent for the treatment of chronic graft-versus-host disease. MMF is rapidly absorbed after oral administration and hydrolyzed to the active metabolite, MPA (mycophenolic acid). MPA selectively inhibits inosine monophosphate dehydrogenase, blocking the pathway of purine synthesis in T and B lymphocytes. In this study we will combine MMF and imatinib mesylate to treat steroid-refractory sclerotic/fibrotic type chronic GVHD to see the response rate and to find the safety of combination.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Children With Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-host Disease
Study Start Date : August 2013
Actual Primary Completion Date : February 14, 2018
Actual Study Completion Date : February 14, 2018

Arm Intervention/treatment
Experimental: Imatinib mesylate, Mycophenolate mofetil

MMF 15-20mg/kg (Max 1 g) bid + Imatinib mesylate qd

  • Dose of imatinib : starting dose 260 mg/m2/d (Max. 400 mg)
  • Imatinib dose adjustment : Dose is adjusted according to the guidelines if there is serious adverse event, toxicity, or intolerance.
Drug: Imatinib mesylate, Mycophenolate mofetil
Other Name: Glivec, Cellcept

Primary Outcome Measures :
  1. Overall (complete and partial) response rate [ Time Frame: 1 year ]

    Response evaluation will be performed every 3 months during the treatment by comprehensive response criteria based on NIH criteria. The complete and partial response categories apply only to organs that have measurable and reversible GVHD-related abnormalities at baseline.

    • Complete response (CR): Resolution of all signs and symptoms of chronic GVHD
    • Partial response (PR) : Improvement (at least 1 clinical score reduction, see Appendix 2) in 1 or more organs of involvement and no evidence of worsening in any organ
    • Objective response (OR): Either CR or PR

Secondary Outcome Measures :
  1. Evaluate the safety profile of MMF plus imatinib mesylate [ Time Frame: 1 year ]

    All adverse events will be recorded on the "Adverse Events CRF" with the following information

    • Severity grade (NCI CTCAE ver. 4.0)
    • Relationship to the study drug
    • Duration (start and end dates or if continuing at final exam)
    • Whether it constitutes a serious adverse event (SAE)

  2. Evaluate the quality of life (QOL) [ Time Frame: 1 year ]
    The assessment of QOL will be performed at baseline and every 3 months till 1 year with Lee cGVHD Symptom Scale.

  3. Discontinuation of steroid [ Time Frame: 1 year ]
    • Based on the response during study period, investigators could modify the dosage of concomitant immunosuppressive agents in the same manner as corticosteroid.
    • The rate of discontinuation among patients and the dose change from baseline of each patient.

  4. Overall survival rate [ Time Frame: 1 year ]
    For survival outcome, Kaplan-Meier method will be used for estimation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Patients must have a diagnosis of chronic GVHD with fibrotic/scleroderma-like features. This diagnosis can be made clinically or by histopathology.
  • Patients must have active disease with at least one of the following manifestations: skin sclerosis, symptomatic bronchiolitis obliterans, extensive lung fibrosis, pathologically demonstrated visceral fibrotic involvement of the gut.
  • Patients with corticosteroid refractory or dependant cGVHD are eligible. Steroid-refractory chronic GVHD is defined as chronic GVHD of sustained severity during the last full month during which the patients received the equivalent of prednisone 0.5 mg/kg or more per day or 1 mg/kg or more every other day.
  • Age under 21 years old

Exclusion criteria

  • Patients who have had chemotherapy, radiotherapy within 4 weeks prior to entering the study.
  • Patients who have not recovered from adverse events.
  • Prior treatment with imatinib mesylate or other tyrosine kinase inhibitor after the date of transplant.
  • Patients on pregnancy or lactating

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01898377

Layout table for location information
Korea, Republic of
Seoul National University Children's Hospital
Seoul, Chongno-gu, Korea, Republic of
Sponsors and Collaborators
Seoul National University Hospital
Layout table for investigator information
Principal Investigator: Hyoung Jin Kang, MD, Ph.D Seoul National University Children's Hospital
Layout table for additonal information
Responsible Party: Seoul National University Hospital Identifier: NCT01898377    
Other Study ID Numbers: SNUCH-1301
First Posted: July 12, 2013    Key Record Dates
Last Update Posted: October 23, 2020
Last Verified: October 2020
Keywords provided by Seoul National University Hospital:
Chronic graft-versus-host disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases
Mycophenolic Acid
Imatinib Mesylate
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors